Pancreatic Cancer Research

ResearcherUniversity of PisaActive in the last 2 years

Luca Morelli

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-7742-9556; OpenAlex author ID A5026222416, A5135276023. Sources: ClinicalTrials.gov.

Their work

Papers
49 (first author 0, last author 6)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
139
Papers, trials and grants by year

2018: 1 trial · 2019: none · 2020: 4 papers · 2021: 9 papers · 2022: 4 papers · 2023: 12 papers · 2024: 8 papers · 2025: 6 papers · 2026: 6 papers

Papers 49

  1. Pancreatic cancer surgery in Italy: an updated snapshot from a national multicentre analysis of outcomes by hospital volume. Co-author DOI 10.1007/s13304-026-02813-5↗
  2. Multicenter IGoMIPS Registry-based analysis of robotic versus laparoscopic approach to left pancreatectomy for pancreatic cancer. Co-author DOI 10.1007/s13304-026-02831-3↗
  3. The emerging role of AXL in pancreatic cancer: Biomarker potential and therapeutic targeting to counteract drug resistance. Co-author DOI 10.1016/j.drup.2026.101408↗
  4. Integrating biomarkers, experimental models, genomics, and novel therapeutics for pancreatic cancer precision medicine. Co-author DOI 10.1016/j.semcancer.2025.12.001↗
  5. Proteomics of Extracellular Vesicles Derived from Primary Cells of Pancreatic Ductal Adenocarcinoma Patients Identifies Ribosomal Proteins Associated with Surv… Co-author DOI 10.1021/acs.jproteome.6c00168↗
  6. Young Age Is Associated with Improved Survival After Resection of Non-Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/life16091499↗
  7. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  8. Long-term recurrence of PDAC after resection for IPMN: A narrative review of the literature on clinical and biologic predictors. Last author DOI 10.1016/j.semcancer.2025.06.001↗
  9. Navigating the paradox of senescence and chemoresistance in pancreatic cancer. Co-author DOI 10.1016/j.semcancer.2025.06.007↗
  10. Raman spectroscopy based diagnosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-025-98122-9↗
  11. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  12. Role of Oral Bacteria in Mediating Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.3390/biom15071018↗
  13. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  14. Darifenacin: a promising chitinase 3-like 1 inhibitor to tackle drug resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00280-024-04712-1↗
  15. Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine-nab-paclitaxel in advanced pancreatic cancer. Co-author DOI 10.1016/j.jlb.2024.100152↗
  16. The pan - COVID - AGICT study. The impact of COVID-19 pandemic on surgically treated pancreatic cancer patients. A multicentric Italian study. Co-author DOI 10.1016/j.suronc.2024.102081↗
  17. Association of hypothyroidism with survival in pancreatic cancer: retrospective cohort study. Last author DOI 10.1093/bjsopen/zrad119↗
  18. Unlocking the diagnostic power of plasma extracellular vesicle miR-200 family in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03090-z↗
  19. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  20. Exploring Splicing Modulation as an Innovative Approach to Combat Pancreatic Cancer: SF3B1 Emerges as a Prognostic Indicator and Therapeutic Target. Co-author DOI 10.7150/ijbs.92671↗
  21. Prediction Model for Early-Stage Pancreatic Cancer Using Routinely Measured Blood Biomarkers. Co-author DOI 10.1001/jamanetworkopen.2023.31197↗
  22. Association between a polymorphic variant in the CDKN2B-AS1/ANRIL gene and pancreatic cancer risk. Co-author DOI 10.1002/ijc.34383↗
  23. Robotic versus laparoscopic distal pancreatectomy for pancreatic adenocarcinoma in obese patients. Co-author DOI 10.1002/rcs.2596↗
  24. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  25. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  26. Thinking small to win big? A critical review on the potential application of extracellular vesicles for biomarker discovery and new therapeutic approaches in p… Co-author DOI 10.1016/j.semcancer.2023.11.003↗
  27. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Co-author DOI 10.1093/carcin/bgad056↗
  28. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jmg-2022-108910↗
  29. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  30. Role of pancreatic ductal adenocarcinoma risk factors in intraductal papillary mucinous neoplasm progression. Co-author DOI 10.3389/fonc.2023.1172606↗
  31. Prognostic Significance of Integrin Subunit Alpha 2 (ITGA2) and Role of Mechanical Cues in Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma (PDAC). Co-author DOI 10.3390/cancers15030628↗
  32. Establishment of Zebrafish Patient-derived Xenografts from Pancreatic Cancer for Chemosensitivity Testing. Co-author DOI 10.3791/63744↗
  33. "Depart from evil, and do good": Turning Axl from uncontrolled tumorigenic gene to biomarker for early detection of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2022.103659↗
  34. Common variability in oestrogen-related genes and pancreatic ductal adenocarcinoma risk in women. Co-author DOI 10.1038/s41598-022-22973-9↗
  35. Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer. Last author DOI 10.3390/diagnostics12020286↗
  36. In Pancreatic Adenocarcinoma Alpha-Synuclein Increases and Marks Peri-Neural Infiltration. Co-author DOI 10.3390/ijms23073775↗
  37. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.33475↗
  38. Organotypic-liver slide culture systems to explore the role of extracellular vesicles in pancreatic cancer metastatic behavior and guide new therapeutic approa… Co-author DOI 10.1080/17425255.2021.1925646↗
  39. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/carcin/bgab057↗
  40. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  41. Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-021-01892-z↗
  42. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  43. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Co-author DOI 10.3389/fonc.2021.771312↗
  44. Zebrafish Patient-Derived Xenografts Identify Chemo-Response in Pancreatic Ductal Adenocarcinoma Patients. Last author DOI 10.3390/cancers13164131↗
  45. Detailing the ultrastructure's increase of prion protein in pancreatic adenocarcinoma. Co-author DOI 10.3748/wjg.v27.i42.7324↗
  46. The occurrence of prion protein in surgically resected pancreatic adenocarcinoma. Last author DOI 10.1016/j.pan.2020.08.004↗
  47. Mendelian randomisation study of the effects of known and putative risk factors on pancreatic cancer. Co-author DOI 10.1136/jmedgenet-2019-106200↗
  48. Mitochondrial DNA Copy-Number Variation and Pancreatic Cancer Risk in the Prospective EPIC Cohort. Co-author DOI 10.1158/1055-9965.epi-19-0868↗
  49. Use of zebrafish embryos as avatar of patients with pancreatic cancer: A new xenotransplantation model towards personalized medicine. Last author DOI 10.3748/wjg.v26.i21.2792↗

Trials 1

  1. Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos Principal investigator NCT03668418↗

Closest collaborators

The 25 strongest of 139 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elisa Giovannetti · 18 shared papers, 2021–2026 · strength 3.64
  2. Annalisa Comandatore · 16 shared papers, 2021–2026 · strength 3.35
  3. Ingrid Garajová · 8 shared papers, 2022–2026 · strength 1.51
  4. Gregorio Di Franco · 9 shared papers, 2020–2025 · strength 1.27
  5. Manuel Gentiluomo · 8 shared papers, 2020–2025 · strength 1.04
  6. Geert Kazemier M · 6 shared papers, 2021–2026 · strength 1.00
  7. Benoît Immordino · 4 shared papers, 2022–2026 · strength 0.81
  8. Daniele Campa · 6 shared papers, 2020–2025 · strength 0.76
  9. Mahrou Vahabi · 3 shared papers, 2023–2026 · strength 0.71
  10. Federico Canzian · 5 shared papers, 2020–2023 · strength 0.56
  11. Hanneke W.M. van Laarhoven · 4 shared papers, 2021–2024 · strength 0.53
  12. Niccola Funel · 5 shared papers, 2020–2021 · strength 0.52
  13. Geng Xu · 2 shared papers, 2025 · strength 0.51
  14. Lenka N.C. Boyd · 3 shared papers, 2023–2024 · strength 0.49
  15. Jisce R. Puik · 3 shared papers, 2023–2024 · strength 0.48
  16. Marc G. Besselink · 3 shared papers, 2023–2024 · strength 0.48
  17. Adam Enver Frampton · 3 shared papers, 2023–2024 · strength 0.48
  18. Rita Balsano · 3 shared papers, 2022–2024 · strength 0.48
  19. Mjriam Capula · 3 shared papers, 2022–2023 · strength 0.48
  20. Vittoria Raffa · 3 shared papers, 2020–2023 · strength 0.45
  21. Alice Usai · 3 shared papers, 2020–2023 · strength 0.45
  22. Tessa Y. S. Le Large · 3 shared papers, 2021–2024 · strength 0.43
  23. Matteo Bianchini · 4 shared papers, 2020–2022 · strength 0.42
  24. Amir Avan · 2 shared papers, 2023–2024 · strength 0.38
  25. Chiara Corradi · 2 shared papers, 2023–2025 · strength 0.36

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.